Monte Rosa Therapeutics Inc (GLUE) returns
Monte Rosa Therapeutics returns over 5 years
$1,000 invested in Monte Rosa Therapeutics five years ago was worth $458.85 at the close on October 30, 2026, with dividends reinvested: an average return of -14.4% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -9.8% | — | $901.93 | -0.9% |
| 3 months | -52.6% | — | $474.43 | +2.1% |
| Year to date | -31.4% | — | $686.22 | +11.7% |
| 1 year | -17.3% | — | $827.06 | +12.4% |
| 3 years | +247.1% | +51.4% | $3,471 | +88.5% |
| 5 years | -54.1% | -14.4% | $458.85 | +76.0% |
Monte Rosa Therapeutics return by calendar year
| Year | GLUE | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -31.4% | +11.7% | -43.1% |
| 2025 | +125.9% | +17.7% | +108.2% |
| 2024 | +22.8% | +24.9% | -2.1% |
| 2023 | -25.8% | +26.2% | -51.9% |
| 2022 | -62.7% | -18.2% | -44.6% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also:
No forecast, no recommendation. This page describes Monte Rosa Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.